Methods of treating pain using antagonists of IL-31, IL-31RA and/or OSMRB

• US 7,943,132 B2
• Filed: 10/28/2009
• Issued: 05/17/2011
• Est. Priority Date: 01/10/2006
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Bilsborough, Janine, Yao, Yue
• Primary Examiner(s): Saoud; Christine J
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US12/607,831
• Publication Number:
  US 20100297125A1
• Time in Patent Office: 566 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Claims

1. A method of treating pain in a mammal in need thereof, comprising administering to the mammal an IL-31RA or Oncostatin M receptor beta (OSMRB) antagonist, wherein said antagonist is an antibody or soluble receptor, and wherein the pain is reduced, limited, minimized or neutralized.

2. The method of claim 1, wherein the IL-31RA or OSMRB antagonist binds a polypeptide comprising the amino acid sequence of SEQ ID NO:

2 from residue 27 to residue 164.

3. The method of claim 1, wherein said antagonist is an antibody binding IL-31RA, OSMRb or both.

4. The method of claim 1, wherein the antagonist is a soluble receptor comprising one or more soluble IL-31RA subunits.

5. The method of claim 1, wherein the antagonist is administered to neuronal tissue comprising dorsal root ganglion or spinal cord tissues.

6. The method of claim 3 wherein said antibody is selected from the group consisting of:

anti-idiotype antibodies;

antibody fragments;

bispecific antibodies;

diabodies, linear antibodies, multivalent antibodies, multispecific antibodies;

chimeric antibodies; and

humanized antibodies.

7. The method of claim 6 wherein said antibody fragment is selected from the group of fragments consisting of:

Fab, Fab′

;

F(ab′

)₂;

Fv and single chain antibodies.

8. The method of claim 3 wherein said antibody is an isotype selected from the group consisting of:

IgG;

IgG1;

IgG4;

IgM;

IgA;

IgD; and

IgE.

9. The method of claim 8 wherein said isotype is IgG.

10. The method of claim 3 wherein said antibody is a monoclonal antibody.

11. The method of claim 3 wherein said antibody is a humanized monoclonal antibody.

12. The method of claim 11 wherein said antibody is an IgG isotype.

13. The method of claim 4 wherein said soluble IL-31RA subunit comprises the amino acid sequence of SEQ ID NO:

20.

14. The method of claim 4 wherein said soluble receptor is a soluble multimer.

15. The method of claim 14 wherein said multimer is a heterodimer comprising a soluble IL-31RA subunit and an OSMRB subunit.

16. A method of reducing pain in a patient in need thereof comprising administering an antibody that antagonizes the IL-31RA subunit, wherein said antibody is a monoclonal antibody.

17. The method of claim 16 wherein said monoclonal antibody is a humanized monoclonal antibody.

18. The method of claim 16 wherein said antibody is an IgG isotype.

19. A method of reducing pain in a patient in need thereof comprising administering a soluble receptor comprising one or more soluble IL-31RA subunits.

20. The method of claim 19 wherein said soluble receptor is a heterodimer comprising a soluble IL-31RA subunit and an OSMRB subunit.

21. A method of reducing pain in a patient in need thereof comprising administering an antibody that antagonizes a heterodimer comprising an IL-31RA subunit and an OSMRB subunit, wherein said antibody is a monoclonal antibody.

22. The method of claim 21 wherein said monoclonal antibody is a humanized monoclonal antibody.

23. The method of claim 21 wherein said antibody is an IgG isotype.